ReviewAnti-cancer agents in medicinal chemistry2026
Disrupting Cancer Pathways with Nanogel-Encapsulated Wheatgrass Phytopharmaceuticals for Skin Cancer Therapy.
Review in Anti-cancer agents in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSkin cancer is a major global health concern, with rising prevalence and limited effectiveness of conventional therapies. Natural phytopharmaceuticals, particularly those derived from Triticum aestivum (wheatgrass), offer promising therapeutic potential due to their antioxidant, anti-inflammatory, and anticancer properties. This review explores the potential of nanogel-encapsulated wheatgrass bioactives to modulate molecular pathways involved in skin cancer development.
methodsA comprehensive review was conducted of preclinical studies, advances in nanogel-based delivery systems, and the molecular pharmacology of wheatgrass phytoconstituents. Emphasis was placed on their interactions with key cancer-related signaling pathways and the impact of nanogels on pharmacokinetic and pharmacodynamic profiles.
resultsWheatgrass bioactives were found to regulate oncogenic pathways, including PI3K/Akt, MAPK/ERK, NF-κB, and p53. Nanogel encapsulation enhanced solubility, stability, targeted delivery, and bioavailability. Both in vitro and in vivo studies demonstrated improved cytotoxicity against melanoma and non-melanoma skin cancer cells, with reduced off-target effects. DISCUSSION: Nanogel-based delivery of wheatgrass phytopharmaceuticals offers a multi-targeted strategy by modulating multiple cancer pathways while addressing challenges associated with natural compound delivery. Despite promising preclinical results, translational limitations remain, including scarce human trials and variability in formulation. Future research should prioritize clinical validation and regulatory standardization.
conclusionNanogel-encapsulated wheatgrass bioactives represent a novel, mechanism-driven, and targetspecific approach for skin cancer therapy, with the potential to advance phytotherapy toward mainstream oncology treatment.
Indexed as
Identifiers
41572701What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.